Ecm.clinexprheumatol.org

SECOND EULAR COURSE ON SYSTEMIC LUPUS ERYTHEMATOSUS
San Miniato, Italy – September 4 – 9, 2005
SUNDAY 4 SEPTEMBER 2005

MONDAY 5 SEPTEMBER 2005
Pharmacodynamics and pharmacokinetics of traditional and new drugs in SLE

8.30-8.50
Pharmacogenomics: a key for understanding drugs response in SLE
11.15-11.45 F. Houssiau
Statins, anticoagulant and antithrombotic drugs
Therapy of SLE: safety

14.30-15.00 O. Di Munno
Drug therapy and prevention of infertility in SLE Drug therapy and toxicity in pregnancy and lactation in SLE Stem cel transplantation in SLE and other autoimmune diseases
TUESDAY 6 SEPTEMBER 2005
Kidney involvement

8.30-9.00
Role of anti-chromatin autoantibodies in the pathogenesis of lupus nephritis Other pathogenetic antibodies in lupus nephritis Clinical picture and monitoring: 9.30-10.00 C. Ponticel i Histological and clinical features of lupus nephritis Optimizing the clinical monitoring of lupus nephritis and evaluation of prognostic factors in lupus nephritis Therapeutic algorhytms in lupus nephritis 11.30-13.00 Discussion of clinical cases Particular issues 14.30-15.00 M.A. Khamashta Pregnancy and SLE 15.00-15.30 F. Conti 15.30-16.00 C.M. Montecucco Fever and SLE 16.00-16.30 M. Mosca Undifferentiated connective tissue diseases
WEDNESDAY 7 SEPTEMBER 2005
CNS involvement
8.30-9.00
G. Riemekasten Pathogenesis of central nervous system involvement in Neurological manifestations of CNS involvement in SLE Fatigue and psychiatric manifestations in SLE. Optimizing the diagnosis and the clinical monitoring of CNS involvement in SLE Therapeutic algorhytms of neurological involvement in SLE. 11.30-13.00 Discussion of clinical cases THURSDAY 8 SEPTEMBER 2005
Therapy of SLE: From bench to the bedside

9.00-10.00 J. Kalden:
Pathogenesis as a clue for targeted therapies for SLE Prospects of biological therapies in SLE Rituximab, CTLA4-Ig and peptide treatment in SLE Autoantibodies in clinical practice in SLE patients
Skin manifestation

14.30-15.00 R. Rondinone:
Diagnosis and differential diagnosis of cutaneous involvement in SLE Treatment of cutaneous involvement in SLE 15.30-17.00 Discussion of clinical cases FRIDAY 9 SEPTEMBER 2005

Measures to assess and monitoring a patient with SLE and response to therapy:
creation of a data base for SLE patients

8.30-9.00
The assessment of quality of life in SLE Development of a responder Index for SLE The core set variables to monitor patients with SLE Atherosclerosis and autoimmunity: the example of SLE
Afternoon

14.30-15.00 Report of the results of a questionnaire on renal involvement
15.00-15.30 Report of the results of a questionnaire on cutaneous involvement
15.30-16.00 Report of the results of a questionnaire on neurological involvement

Credits and departures

Source: http://ecm.clinexprheumatol.org/corsi/programmi/32.pdf